Modality
siRNA
MOA
PARPi
Target
HER2
Pathway
Lipid Met
UCPBC
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
~May 2018
→ ~Aug 2019
Phase 2
~Nov 2019
→ ~Feb 2021
Phase 3
~May 2021
→ ~Aug 2022
NDA/BLA
Nov 2022
→ Dec 2029
NDA/BLACurrent
NCT08636255
2,002 pts·UC
2022-11→2029-12·Active
2,002 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-12-243.7y awayPh3 Readout· UC
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
NDA/BLA
Active
Catalysts
Ph3 Readout
2029-12-24 · 3.7y away
UC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08636255 | NDA/BLA | UC | Active | 2002 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP |